How Can We Help? A Guide to Substance Use Disorders, Stigma, and Harm Reduction

For people with a substance use disorder, stigma is a major barrier to recovery. When someone discloses their struggles with substance use, they risk being stigmatized by their families, friends, and even health care providers. Some treatment strategies, including harm reduction, are also stigmatized, making it difficult for people to access resources. Harm reduction is a set of strategies based on the core value of respect for the rights of people who use drugs. The goal of harm reduction is to help people stay safe while using substances and to connect them with medical professionals who offer evidence-based treatment for substance use disorders. Because harm reduction strategies do not require abstinence from substance use, they are often misunderstood as enabling drug use. This guide is meant to help people understand the role of stigma in preventing people from accessing recovery resources. It provides an overview of harm reduction strategies and explains the research on best practices for supporting people with substance use disorders to use substances more safely, and to help them consider options for treatment and recovery. The guide is in graphic novel format, and follows Erin, Hilary and Leo the Chihuahua as they travel to beautiful destinations in Utah and talk about these topics.https://digitalcommons.usu.edu/harmreductioncomics/1002/thumbnail.jp

The Ever-Shifting Internet Population

Presents findings from surveys conducted between March and May 2002. Takes a new look at Internet access and the digital divide. Explores factors of cost, lack of technology skills, and physical access (particularly for persons with disabilities)

The Urban/Rural Divide in Access to Medication-Assisted Treatment for Opioid Use Disorder in Utah

Death by drug poisoning is the leading cause of death due to injury in the state of Utah (UDOH, 2014). From 2013-2015, Utah ranked seventh in the nation for drug overdose deaths, the majority of which were opioid-related (CDC, 2018a). In 2017, the age-adjusted mortality rate from drug overdose in Utah was 15.5 per 100,000, putting the state above the national average of 14.9 per 100,000 (CDC, 2018b). Opioid overdose death rates in most of rural Utah far exceeds rates across the urban counties of the state. The higher rates of deaths in rural Utah is indeed concerning. Evidence indicates that rural areas are particularly hard hit due to limited access to care and resources (USDA, 2019). Three kinds of medication-assisted treatment (MAT) approved for treatment of opioid use disorder (OUD) include: methadone, buprenorphine, and naltrexone (SAMHSA, 2019a). These medications block the euphoric effect of drugs, relieve cravings, and stabilize brain chemistry without the negative side effects of the previously abused drug (SAMHSA, 2019b). This fact sheet gives details about MAT for opioid use disorder

Examination of Anger Prevalence in NCAA Division I Student-Athletes

Purpose: Anger associated with sports participation may affect inability to acutely process anger, may decrease performance and increase the likelihood of risk-taking behavior in collegiate athletes. Therefore, the purpose was to examine the prevalence of anger in collegiate student-athletes across sex, academic status, and sport type. Methods: A cross sectional study over a three-year period examined 759 NCAA Division I student-athletes at one institution (age=20±1 years; males: n=259; females: n=500) completed an optional pre-participation behavioral health screening questionnaire, personal demographic information and the Anger Index Self-Test. Results: Overall, 37.2% (n=282/759; males=127/259, 49.0%; females=155/500, 31.0%) of participants were at high-risk for anger. We identified a significant difference between the anger and sex [Χ2(2, N=759) =28.1, P≤0.01]. We also identified a significant difference between the anger and sport type [Χ2(8, N=759)=32.1, P≤0.01] with 55.2% (n=419/759) at moderate risk for anger despite sport type; with the highest percentages presenting high-risk for anger within power sports (n= 64/116, 55.2%) and ball sports (n=98/240, 40.8%). No significant differences were identified for anger risk and academic status (P=0.66). Conclusions: Female collegiate student-athletes demonstrated a higher prevalence of anger than male collegiate student-athletes, yet more males were high-risk. Most student-athletes displayed moderate-risk for anger across different sports. Anger across academic status was not significantly different implying that anger management and coping skills may need to be taught during their student-athlete tenure to mitigate the identified risk. A collegiate student-athlete’s inability to process anger may affect sports performance and have negative consequences on their personal and social life. A primary prevention mechanism exists to explore proper coping mechanisms for anger during sport before the onset of mental health conditions that could exacerbate the experience for the individual

Opioid Use Disorder (OUD) and Pregnancy in Utah

Over the past twenty years, opioid use during pregnancy has become much more common (Haight et al., 2018). Opioids may be prescribed for pain management or the treatment of an opioid use disorder (OUD). For example, methadone or buprenorphine are medications recommended for pregnant women with OUD. Opioid use may also include misusing prescription painkillers or using illicit drugs such as heroin. Regardless of the nature of opioid use, it is important for pregnant women to know how opioid use can impact their pregnancy and what treatment options are available

A Crisis of Her Own: Fatal Opioid Overdose, Opioid Use Disorder, and Intimate Partner Violence Among Rural Utah Women

The Centers for Disease Control report that the rate of overdose deaths among women is rapidly increasing, with women experiencing a 532% increase in fatal opioid overdose deaths between 1999 and 2017, compared to a 355% increase for men. Among women, those in rural areas have disproportionately higher drug overdose death rates than women in urban areas (Mazure & Fiellin, 2018), indicating an opportunity for targeted rural public health interventions to slow overdose fatality increases among women. This fact sheet reviews Utah trends, potential factors increasing fatal opioid overdose, intimate partner violence and substance use disorders, and provides resources for getting help

Taking the next-gen step: Comprehensive antimicrobial resistance detection from Burkholderia pseudomallei

Background: Antimicrobial resistance (AMR) poses a major threat to human health. Whole-genome sequencing holds great potential for AMR identification; however, there remain major gaps in accurately and comprehensively detecting AMR across the spectrum of AMR-conferring determinants and pathogens. Methods: Using 16 wild-type Burkholderia pseudomallei and 25 with acquired AMR, we first assessed the performance of existing AMR software (ARIBA, CARD, ResFinder, and AMRFinderPlus) for detecting clinically relevant AMR in this pathogen. B. pseudomallei was chosen due to limited treatment options, high fatality rate, and AMR caused exclusively by chromosomal mutation (i.e. single-nucleotide polymorphisms [SNPs], insertions-deletions [indels], copy-number variations [CNVs], inversions, and functional gene loss). Due to poor performance with existing tools, we developed ARDaP (Antimicrobial Resistance Detection and Prediction) to identify the spectrum of AMR-conferring determinants in B. pseudomallei. Findings: CARD, ResFinder, and AMRFinderPlus failed to identify any clinically-relevant AMR in B. pseudomallei; ARIBA identified AMR encoded by SNPs and indels that were manually added to its database. However, none of these tools identified CNV, inversion, or gene loss determinants, and ARIBA could not differentiate AMR determinants from natural genetic variation. In contrast, ARDaP accurately detected all SNP, indel, CNV, inversion, and gene loss AMR determinants described in B. pseudomallei (n≈50). Additionally, ARDaP accurately predicted three previously undescribed determinants. In mixed strain data, ARDaP identified AMR to as low as ~5% allelic frequency. Interpretation: Existing AMR software packages are inadequate for chromosomal AMR detection due to an inability to detect resistance conferred by CNVs, inversions, and functional gene loss. ARDaP overcomes these major shortcomings. Further, ARDaP enables AMR prediction from mixed sequence data down to 5% allelic frequency, and can differentiate natural genetic variation from AMR determinants. ARDaP databases can be constructed for any microbial species of interest for comprehensive AMR detection